TCG Japan Regional Forum shines spotlight on IoT security
Beaverton, OR, USA, June 29, 2022 – As society becomes increasingly dependent on IoT devices,…
News
ALIO Industries Makes Strategic Appointment
(29th June 2022, Arvada, CO, USA) Leading nanometer-level motion control solutions innovator ALIO Industries, is…
Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication
Newly Issued Patent Broadens Medical Uses of Oral APX3330 Therapy in Patients with Diabetes and…
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares and Pre-Funded Warrants
JERSEY, Channel Islands, June 29, 2022 (GLOBE NEWSWIRE) — Quotient Limited (Nasdaq: QTNT) (the “Company”),…
Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function
Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies,…
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company”…
Novozymes’ financial calendar 2023
Read the full announcement in PDF Attachment 2022_24_Financial_calendar_2023
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic…
Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value
Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON,…
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735
Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo…
Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders
Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision…
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
Phase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion…
Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer
Industry veteran brings over two decades of global experience in pharmaceutical, medical devices and biotech…
Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options
— HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up…
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment…
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
exoASO-STAT6 is the third engineered exosome candidate generated from Codiak’s engEx® Platform to enter clinical…
Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation
SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation…
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
Leverages Mindset’s Platform Technology for Efficient Delivery of CNS Therapeutics TORONTO, June 29, 2022 (GLOBE…
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMA…